Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 13 | 2025 | 590 | 5.600 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 4 | 2025 | 37 | 3.450 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2025 | 38 | 2.680 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 832 | 1.690 |
Why?
|
| Blood Pressure | 10 | 2025 | 513 | 1.660 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 123 | 1.620 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2025 | 57 | 1.390 |
Why?
|
| Antihypertensive Agents | 4 | 2021 | 171 | 1.360 |
Why?
|
| Dietary Approaches To Stop Hypertension | 4 | 2023 | 9 | 1.340 |
Why?
|
| Troponin I | 3 | 2025 | 36 | 1.190 |
Why?
|
| Peptide Fragments | 4 | 2025 | 411 | 1.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2024 | 33 | 1.090 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 116 | 1.090 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 72 | 1.090 |
Why?
|
| Cardiac Rehabilitation | 2 | 2025 | 67 | 1.060 |
Why?
|
| Pregnancy | 11 | 2025 | 2316 | 1.020 |
Why?
|
| Telemedicine | 3 | 2025 | 318 | 0.980 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 142 | 0.950 |
Why?
|
| Contraception | 2 | 2022 | 71 | 0.900 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 21 | 0.890 |
Why?
|
| Echocardiography | 5 | 2024 | 498 | 0.870 |
Why?
|
| Heart Failure | 4 | 2023 | 900 | 0.850 |
Why?
|
| Mobile Applications | 1 | 2025 | 136 | 0.810 |
Why?
|
| Female | 34 | 2025 | 32491 | 0.800 |
Why?
|
| Contraceptive Effectiveness | 1 | 2022 | 3 | 0.780 |
Why?
|
| Patient Compliance | 1 | 2024 | 358 | 0.770 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 164 | 0.770 |
Why?
|
| Adult | 23 | 2025 | 16626 | 0.770 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 12 | 0.770 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 129 | 0.770 |
Why?
|
| Humans | 45 | 2025 | 62681 | 0.740 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 23 | 0.730 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 128 | 0.690 |
Why?
|
| Qualitative Research | 1 | 2024 | 670 | 0.660 |
Why?
|
| Cardiology | 1 | 2022 | 167 | 0.660 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 9 | 0.650 |
Why?
|
| Young Adult | 9 | 2025 | 4633 | 0.640 |
Why?
|
| C-Reactive Protein | 4 | 2025 | 166 | 0.600 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 176 | 0.590 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 131 | 0.520 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2540 | 0.460 |
Why?
|
| Risk Factors | 8 | 2025 | 5302 | 0.440 |
Why?
|
| Health Surveys | 1 | 2015 | 312 | 0.440 |
Why?
|
| Biomarkers | 7 | 2025 | 1385 | 0.420 |
Why?
|
| Middle Aged | 17 | 2025 | 17364 | 0.420 |
Why?
|
| United States | 10 | 2024 | 7719 | 0.400 |
Why?
|
| Stroke Volume | 3 | 2023 | 328 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 725 | 0.360 |
Why?
|
| Sinusitis | 1 | 2011 | 30 | 0.360 |
Why?
|
| Vital Capacity | 1 | 2011 | 110 | 0.360 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 198 | 0.350 |
Why?
|
| Endoscopy | 1 | 2011 | 108 | 0.340 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 118 | 0.340 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 83 | 0.320 |
Why?
|
| Gout | 3 | 2015 | 48 | 0.310 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 775 | 0.300 |
Why?
|
| Heart | 3 | 2019 | 282 | 0.300 |
Why?
|
| Aged | 10 | 2025 | 14255 | 0.280 |
Why?
|
| Furosemide | 2 | 2018 | 21 | 0.270 |
Why?
|
| Sodium | 2 | 2023 | 62 | 0.260 |
Why?
|
| Diuretics | 2 | 2018 | 63 | 0.260 |
Why?
|
| Male | 17 | 2025 | 29486 | 0.260 |
Why?
|
| High-Intensity Interval Training | 1 | 2025 | 2 | 0.240 |
Why?
|
| HMGB1 Protein | 1 | 2025 | 26 | 0.240 |
Why?
|
| Glucose | 2 | 2023 | 469 | 0.230 |
Why?
|
| Peripartum Period | 1 | 2024 | 21 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2024 | 215 | 0.220 |
Why?
|
| Smartphone | 1 | 2025 | 69 | 0.220 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 99 | 0.210 |
Why?
|
| Troponin T | 2 | 2023 | 24 | 0.210 |
Why?
|
| Dyspnea | 1 | 2024 | 121 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 217 | 0.200 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2023 | 44 | 0.200 |
Why?
|
| Focus Groups | 1 | 2024 | 299 | 0.200 |
Why?
|
| Heart Ventricles | 2 | 2023 | 261 | 0.200 |
Why?
|
| Electrocardiography | 2 | 2024 | 550 | 0.200 |
Why?
|
| Sterilization, Reproductive | 1 | 2022 | 8 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2024 | 153 | 0.190 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 193 | 0.190 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1110 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2025 | 410 | 0.180 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2021 | 5 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2023 | 144 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 314 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 152 | 0.180 |
Why?
|
| Vital Signs | 1 | 2021 | 11 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 104 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2022 | 196 | 0.180 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 33 | 0.170 |
Why?
|
| Asthma | 1 | 2024 | 433 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2025 | 3258 | 0.160 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 20 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2024 | 469 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 42 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 61 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 161 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 268 | 0.150 |
Why?
|
| Aortic Valve | 1 | 2021 | 189 | 0.150 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 109 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 658 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 686 | 0.140 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 188 | 0.140 |
Why?
|
| Curriculum | 1 | 2022 | 585 | 0.140 |
Why?
|
| Dopamine | 1 | 2018 | 105 | 0.140 |
Why?
|
| Uric Acid | 2 | 2015 | 47 | 0.140 |
Why?
|
| Triage | 1 | 2018 | 118 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2024 | 6536 | 0.140 |
Why?
|
| Atrial Appendage | 1 | 2017 | 33 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2017 | 51 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 226 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2017 | 34 | 0.130 |
Why?
|
| Myocarditis | 1 | 2017 | 66 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 1602 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 280 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 39 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 230 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2023 | 1341 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 263 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 16 | 0.100 |
Why?
|
| Clonidine | 1 | 2012 | 25 | 0.100 |
Why?
|
| Oxycodone | 1 | 2012 | 30 | 0.100 |
Why?
|
| Narcotics | 1 | 2012 | 58 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5591 | 0.090 |
Why?
|
| Analgesics | 1 | 2012 | 102 | 0.090 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 49 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1230 | 0.090 |
Why?
|
| Comorbidity | 2 | 2013 | 1118 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 174 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 2039 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 1159 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 154 | 0.080 |
Why?
|
| Prevalence | 3 | 2024 | 1348 | 0.080 |
Why?
|
| Diet | 2 | 2023 | 523 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 835 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 933 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 45 | 0.070 |
Why?
|
| Stroke | 1 | 2017 | 1189 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 102 | 0.070 |
Why?
|
| Adolescent | 2 | 2025 | 6172 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1247 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 533 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2008 | 157 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 469 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5406 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2011 | 1937 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2539 | 0.060 |
Why?
|
| Peptide Nucleic Acids | 1 | 2004 | 16 | 0.060 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2004 | 15 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 43 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2024 | 21 | 0.050 |
Why?
|
| Home Care Services | 1 | 2025 | 98 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 113 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 128 | 0.050 |
Why?
|
| Pericardium | 1 | 2023 | 34 | 0.050 |
Why?
|
| Hospitalization | 2 | 2025 | 1344 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1066 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 100 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 149 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 93 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 138 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 112 | 0.050 |
Why?
|
| Vegetables | 1 | 2022 | 67 | 0.050 |
Why?
|
| Child | 1 | 2011 | 4444 | 0.050 |
Why?
|
| Systole | 1 | 2021 | 109 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 83 | 0.040 |
Why?
|
| Smoking | 1 | 2024 | 864 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 109 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 11 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 156 | 0.040 |
Why?
|
| Creatinine | 1 | 2018 | 135 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 173 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 1 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3387 | 0.030 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2017 | 16 | 0.030 |
Why?
|
| Hyperemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 463 | 0.030 |
Why?
|
| Ammonia | 1 | 2017 | 15 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 72 | 0.030 |
Why?
|
| Vasodilation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 95 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 670 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 223 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 51 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2017 | 51 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 160 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1138 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 186 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2445 | 0.030 |
Why?
|
| Therapeutics | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice | 2 | 2025 | 10804 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 482 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 376 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1077 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 161 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 308 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2017 | 494 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 933 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 862 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 183 | 0.020 |
Why?
|
| Animals | 2 | 2025 | 20581 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 435 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 130 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1589 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 837 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3742 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 108 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 271 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 189 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 456 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 453 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2008 | 519 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 173 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 610 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 937 | 0.020 |
Why?
|
| Mitochondria | 1 | 2008 | 366 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2008 | 623 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 981 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 898 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1601 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 839 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 3022 | 0.010 |
Why?
|